IASIS PHARMA is pleased to announce the launch of the new Zylapour® 100 mg x 100 tabs package, which expands the existing Zylapour® 100 mg x 30 tabs & Zylapour® 300 mg x 30 packages.
The active substance of Zylapour® is Allopurinol.
Allopurinol is in the class of medications called xanthine oxidase inhibitors and it was approved for medical use in the United States in 1966. It is included in the World Health Organization’s List of Essential Medicines.
Zylapour® as an once-daily single tablet regimen, is the ideal Treatment of Primary and Secondary Hyperuricemia and the Prevention of its Complications, mainly for the Prophylaxis against Gout (primary, secondary)as well as Uric Acid Nephrolithiasis.